Skip to main content
Premium Trial:

Request an Annual Quote

PacBio, Cantor Fitzgerald Amend Deal to Offer up to $30M in Stock

NEW YORK (GenomeWeb) – Pacific Biosciences said on Tuesday that it has amended an agreement with Cantor Fitzgerald to offer up to $30 million of its common stock from time to time. 

The agreement amends a deal that PacBio and Cantor Fitzgerald reached in October to sell up to $30 million of the next-generation sequencing firm's common stock. The amended agreement is for the sale of an additional $30 million, PacBio said in a document filed with the US Securities and Exchange Commission.

Under the terms of the amended deal, Cantor may sell PacBio shares at an "at-the-market" offering, in which shares are offered at the prevailing market prices. Cantor can also sell the shares by other methods, including through privately negotiated deals. PacBio said it intends to use proceeds from the offering for general corporate purposes, such as capital expenditures and working capital.

As of Dec. 31, 2014, PacBio had $101.3 million in cash and investments. On Tuesday, it reported an 85 percent jump in its fourth quarter revenues. 

In August the company raised almost $21 million in an at-the-market offering, and in November, it filed a shelf registration to offer up to $150 million of its securities.

The Scan

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Targets Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.